Bessemer Group’s Oric Pharmaceuticals ORIC Stock Holding History

Bessemer Group’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-120	Closed	-$1K	–	2633
2024 Q3	$1K	Buy	+120	New	+$1.19K	﹤0.01%	2494

Other funds holding ORIC

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bessemer Group's ORIC Position: Q4 2024 in Review

Bessemer Group sold out of Oric Pharmaceuticals (ORIC) in Q4 2024, closing a stake of 120 shares — an estimated $1K sold.

Bessemer Group first reported a position in ORIC in Q3 2024 and held it in 1 quarter. The position peaked at $1K in Q3 2024. 129 funds tracked by Wall St. Rank hold ORIC as of Q4 2024.

Bessemer Group reported no remaining Oric Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Bessemer Group sold 120 Oric Pharmaceuticals shares in Q4 2024, an estimated $1K.
Bessemer Group first reported a position in Oric Pharmaceuticals in Q3 2024 and held it in 1 quarter.
Bessemer Group's Oric Pharmaceuticals position peaked at $1K in Q3 2024.
129 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q4 2024.

Based on Bessemer Group's 13F filing for Q4 2024, filed 13 Feb 2025.